Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Conclusions: The findings suggest that considering the routine availability of blood cell count data before the initiation of treatment with pembrolizumab, it may be useful in identifying early-onset irAEs during the 6-weeks study period in clinical practice.

http://www.jcancer.org/v12p2105.htm

Source: Journal of Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura, Koichi Fukunaga, Masakazu Yamaguchi, Tomonori Nakamura Tags: Research Paper Source Type: research

More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study